We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DOUG:NYSEDouglas Elliman Inc. Analysis

Data as of 2026-07-27 - not real-time

$1.74

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Douglas Elliman (DOUG) is trading at $1.74, well below its 20‑day ($1.85) and 50‑day ($1.79) simple moving averages and also under its 200‑day SMA ($2.19), indicating a bearish technical backdrop. The RSI sits at 43, the MACD histogram is negative and the signal line is bearish, while volume is on a downtrend, all of which reinforce short‑term downside pressure. At the same time, the stock exhibits high volatility (43% 30‑day) and a beta of ~1.8, suggesting amplified moves relative to the market and a heightened risk profile. Despite a trailing P/E of 34.8 that exceeds the industry average of 32.9, the forward P/E of 19.3 and a DCF‑derived fair value of $3.28 imply that the market may be undervaluing the company, as the current price is roughly half of the intrinsic estimate. Revenue has contracted 15% YoY and operating margins remain negative, yet free cash flow is positive and the price‑to‑book ratio is below 1 (0.91), hinting at a potential value cushion.
The most material catalyst this week is the announcement of a sweeping AI transformation built on Google Cloud, which triggered a 12.3% pre‑market sell‑off. While the AI initiative could eventually lower costs and modernize the brokerage model, the immediate market reaction reflects investor skepticism about execution risk. Coupled with a historic max drawdown of nearly 50% and a modest ROE of 2.6%, the stock faces considerable upside potential if the strategic shift bears fruit, but the path forward remains uncertain.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Bearish technical indicators (price below SMAs, negative MACD)
  • Recent 12.3% pre‑market price drop on AI news
  • High volatility and decreasing volume

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • DCF fair value indicates ~80% upside potential
  • Forward P/E compression suggests earnings improvement
  • Strategic AI rollout could improve margins if executed

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervalued relative to book and DCF estimates
  • Low price‑to‑sales and price‑to‑book ratios
  • Potential long‑term competitive advantage from technology integration

Key Metrics & Analysis

Financial Health

Revenue Growth-15.40%
Profit Margin0.50%
P/E Ratio34.8
ROE2.65%
ROA-3.01%
Debt/Equity60.57
P/B Ratio0.9
Op. Cash Flow$-27603000
Free Cash Flow$23.6M
Industry P/E32.9

Technical Analysis

TrendNeutral
RSI43.1
Support$1.68
Resistance$2.05
MA 20$1.85
MA 50$1.79
MA 200$2.19
MACDBearish
VolumeDecreasing
Fear & Greed Index88.09

Valuation

Fair Value$3.28
GradeUndervalued
TypeBlend

Risk Assessment

Beta1.80
Volatility43.16%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.